Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brainsway ( (BWAY) ) has provided an update.
On October 14, 2025, BrainsWay Ltd. announced that Valor BrainsWay Holdings LLC exercised its warrant to purchase 1,500,000 American Depositary Shares (ADSs) of the company. The exercise was conducted on a cashless basis, resulting in the issuance of 553,730 ADSs to Valor without any cash proceeds for BrainsWay. This move is part of a private placement agreement established in November 2024, and it reflects strategic financial maneuvers by BrainsWay to manage its equity and strengthen its market position.
The most recent analyst rating on (BWAY) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s overall stock score is driven by its strong financial performance and positive earnings call, highlighting significant revenue growth and strategic investments. However, the high valuation and technical indicators suggesting overbought conditions temper the score.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. operates in the medical device industry, specializing in advanced non-invasive neurostimulation treatments for mental health disorders. The company is known for its Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which is used to treat conditions such as depression and obsessive-compulsive disorder.
Average Trading Volume: 65,718
Technical Sentiment Signal: Buy
Current Market Cap: $299.8M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.